Janssen
TSRI and Janssen close in on universal flu vaccine
August 25, 2015Manufacturing and Production Janssen, Vaccine, flu, immunology, universal flu vaccine
Scientists from Janssen and The Scripps Research Institute (TSRI) have found a way to induce antibodies to fight a wide …
European Imbruvica approval for Janssen
July 20, 2015Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer
Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …
Data supports switching to Hospira biosimilar for RA
June 10, 2015Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome
Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …
NICE U-turn on Janssen arthritis drug
June 4, 2015Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn
NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …
EMA recommends eight drugs for approval
May 22, 2015Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda
The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …
J&J blood cancer drug gets UK launch
March 25, 2015Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl
Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Pharma firms pledge vaccine support for developing countries
January 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing GAVI, GSK, Janssen, Médecins Sans Frontières, Pfizer, Vaccine
Several pharma firms have announced commitments to help Gavi, the global vaccine alliance, to increase immunisation of children in developing …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
